Phase 4
Completed N=12
Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation
Constipation Drug Induced
Source: ClinicalTrials.gov NCT03523520 ↗
Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcomePrimary: Occurrence of Bowl Movement — 2; 2; 5 Participants
◆ Published Evidence
Emerging
17citations · ~2 / year
Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
Summary
The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
Linked Publications (2)
-
Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
-
Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Occurrence of Bowl Movement |
2; 2; 5 | — |
| SECONDARY Time to Bowl Movement Within 24 Hours |
292.5; 256.5; 270.2 | — |
Eligibility Criteria
Inclusion Criteria
- Complaint of opioid-induced constipation refractory to other therapy (enemas, laxatives, stool softeners)
- Age≥18y/o
- Not pregnant or lactating (negative urinary pregnancy test)
- No contraindication to Methylnaltrexone or Naloxegol
Exclusion Criteria
- Age<18y/o
- Pregnancy or lactation
- Contraindication to Methylnaltrexone or Naloxegol
- Assigned NPO
- Small bowel obstruction
Data sourced from ClinicalTrials.gov (NCT03523520) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.